(Q42647365)

English

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. (English)

1 reference

Europe PubMed Central

4 November 2017

0 references

steatohepatitis

0 references

0 references

1 reference

based on heuristic

inferred from title

7

object named as

Koji Arihiro

1 reference

Europe PubMed Central

4 November 2017

Kazuaki Chayama

8

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

4 November 2017

2

object named as

Hideyuki Hyogo

1 reference

Europe PubMed Central

4 November 2017

author name string

Yuki Kimura

1

1 reference

Europe PubMed Central

4 November 2017

Sho-ichi Yamagishi

3

1 reference

Europe PubMed Central

4 November 2017

Masayoshi Takeuchi

4

1 reference

Europe PubMed Central

4 November 2017

Tomokazu Ishitobi

5

1 reference

Europe PubMed Central

4 November 2017

Yoshitaka Nabeshima

6

1 reference

Europe PubMed Central

4 November 2017

publication date

30 January 2010

1 reference

Europe PubMed Central

4 November 2017

Journal of Gastroenterology

1 reference

Europe PubMed Central

4 November 2017

45

1 reference

Europe PubMed Central

4 November 2017

7

1 reference

Europe PubMed Central

4 November 2017

750-757

1 reference

Europe PubMed Central

4 November 2017

Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0203-Y

21 January 2018

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0203-Y

21 January 2018

Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0203-Y

21 January 2018

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0203-Y

21 January 2018

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The natural history of nonalcoholic fatty liver: a follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-alcoholic steatohepatitis: another disease of affluence

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiological aspects of obesity and NASH/NAFLD in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Roles of the AGE-RAGE system in vascular injury in diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Report of the expert committee on the diagnosis and classification of diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ethics and morality of clinical trials in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term prognosis of fatty liver: risk of chronic liver disease and death.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycation end products (AGEs) and their involvement in liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/20112031

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-010-0203-Y

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42647365&oldid=1760248415"